The double-edged sword of statin immunomodulation
| Autor: | Luca Mascitelli, Mark R. Goldstein, Francesca Pezzetta |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Statin
medicine.drug_class viruses Hepatitis C virus Population Disease medicine.disease_cause Infections T-Lymphocytes Regulatory Risk Factors Neoplasms medicine Humans Immunologic Factors Amyotrophic lateral sclerosis education Hepatitis B virus education.field_of_study business.industry Varicella zoster virus Cancer Neurodegenerative Diseases medicine.disease Cardiovascular Diseases Immunology lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business |
| Zdroj: | International journal of cardiology. 135(1) |
| ISSN: | 1874-1754 |
| Popis: | Statin drugs are widely prescribed to achieve aggressive low-density lipoprotein lowering in order to decrease cardiovascular disease. Although some of the immunomodulatory effects of statins may stabilize atherosclerotic plaque, they may be harmful in certain segments of the population. Recently, statins have been shown to increase the concentration of regulatory T cells (Tregs), in vivo. There is evidence that this increases the risk of many cancers, particularly in the elderly. Furthermore, a statin induced increase in Tregs may be detrimental in neurodegenerative disorders, such as amyotrophic lateral sclerosis; and a myriad of infectious diseases. These include, but are not limited to, human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and varicella zoster virus. These issues need our attention, and call for a heightened state of vigilance among those prescribing statins. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect